RNAZ
Transcode Therapeutics, Inc.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Apr 7 Transcode Therapeutics secured up to $20 million in flexible financi…
- R Apr 30 TransCode Therapeutics filed an S-3 registration statement to regist…
- R May 26 Transcode Therapeutics received a Nasdaq deficiency notice for faili…
- R Jun 3 TransCode Therapeutics announced successful completion of its Phase…
- X Jul 15 Short interest falls 34.8% to 34.4K
- X Aug 31 Short interest jumps 48.8% to 46.0K
- X Sep 15 Short interest jumps 33.5% to 61.4K
- R Sep 28 TransCode Therapeutics reported updated Phase 1a clinical data for T…
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 1 trimmed or exited.
- Short sellersCOVERING
Short interest −15.2% to 52.1K shares. 1.0 days to cover, ≈0.3% of shares.
- TrendRANGE
13% below its 50-day average.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| UBS Group AG | TRIM | $17.9K |
| UBS Group AG | DOUBLED | $71.4K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Apr 2025| Date | Firm | Rating |
|---|---|---|
| Apr 16, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Mar 13, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Feb 7, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Feb 6, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Dec 18, 2024 | HC Wainwright & Co. MAINTAIN | Buy |
| Nov 15, 2024 | HC Wainwright & Co. REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Sep 9, 2026 | Fitzgerald Thomas A Chief Financial Officer | AWARD | 185,000 sh |
| Aug 3, 2026 | DEFJ, LLC 10%+ Owner | CONVERT | 11,813,859 sh |
| Aug 3, 2026 | DEFJ, LLC 10%+ Owner | CONVERT | 2,020,582 sh |
| Aug 3, 2026 | DEFJ, LLC 10%+ Owner | CONVERT | 1,181.386 sh |
| Aug 3, 2026 | DEFJ, LLC 10%+ Owner | CONVERT | 202.058 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Sep 30, 2026SecBot reports
10 filings · 2 bullish · 4 bearish · 1 mixed · 3 neutral- BULLISH 8-KSep 28, 2026
TransCode Therapeutics reported updated Phase 1a clinical data for TTX-MC138, showing a 71.4%…
These updated Phase 1a data strengthen the clinical case for TTX-MC138, with durable disease control and supportive biomarker evidence. Watch for Phase 2a data in ctDNA-positive colorectal cancer…
- NEUTRAL 3Sep 21, 2026
John A. Tattory filed a Form 3 initial statement of beneficial ownership with the SEC, disclosing…
This is a routine initial ownership filing by a newly appointed officer with no current stake. Monitor for future Form 4 filings that may indicate insider buying or selling activity, which would…
- BEARISH 8-KSep 11, 2026
TransCode Therapeutics CFO Thomas Fitzgerald resigned effective September 9, 2026, and was…
The CFO departure at a micro-cap biotech with a $29M market cap is a negative signal, but the severance structure explicitly ties payments to the company raising $5M or $10M in funding, highlighting…
- NEUTRAL 8-KJul 2, 2026
TransCode Therapeutics adjourned its 2026 Annual Meeting to July 20, 2026, pending Nasdaq's review…
Monitor for Nasdaq's decision on the initial listing application before July 20. Approval would clear the way for the preferred stock conversion vote, potentially increasing share count. Denial…
All RNAZ filing & press-release reports (10)
- 8-K reportSep 28, 2026
- 3 reportSep 21, 2026
- 8-K reportSep 11, 2026
- 8-K reportJul 2, 2026
- 8-K reportJun 18, 2026
- 8-K reportJun 3, 2026
- DEFA14A reportMay 26, 2026
- S-3 reportApr 30, 2026
- 8-K reportApr 7, 2026
- DEFA14A reportMar 3, 2026